{
    "ticker": "KALA",
    "name": "Kala Pharmaceuticals, Inc.",
    "description": "Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for eye diseases. Founded in 2013 and headquartered in Watertown, Massachusetts, Kala is dedicated to addressing significant unmet medical needs in the ophthalmic space. The company's lead product, INVELTYS (ketorolac ophthalmic suspension), is a twice-daily eye drop indicated for the treatment of post-operative inflammation and pain following cataract surgery. This product utilizes Kala's proprietary drug delivery technology, which enhances the bioavailability of medications and provides sustained release for improved patient compliance. Kala is also advancing its pipeline of therapies aimed at conditions such as dry eye disease, with the goal of providing patients with effective and convenient treatment options. Through its scientific expertise and commitment to innovation, Kala Pharmaceuticals is striving to improve the quality of life for patients suffering from debilitating eye conditions. The company\u2019s vision is to transform the treatment landscape in ophthalmology through its cutting-edge research and development efforts.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Watertown, Massachusetts, USA",
    "founded": "2013",
    "website": "https://www.kalarx.com",
    "ceo": "Mark Iwicki",
    "social_media": {
        "twitter": "https://twitter.com/KalaPharma",
        "linkedin": "https://www.linkedin.com/company/kala-pharmaceuticals"
    },
    "investor_relations": "https://investors.kalarx.com",
    "key_executives": [
        {
            "name": "Mark Iwicki",
            "position": "CEO"
        },
        {
            "name": "David W. W. H. Evans",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ophthalmic Products",
            "products": [
                "INVELTYS"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kala Pharmaceuticals, Inc. | Innovative Eye Disease Treatments",
        "meta_description": "Kala Pharmaceuticals, Inc. specializes in innovative therapies for eye diseases. Explore Kala's cutting-edge products and commitment to improving patient outcomes.",
        "keywords": [
            "Kala Pharmaceuticals",
            "Ophthalmology",
            "INVELTYS",
            "Biotechnology",
            "Eye Diseases",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Kala Pharmaceuticals known for?",
            "answer": "Kala Pharmaceuticals is known for developing innovative treatments for eye diseases, particularly its product INVELTYS."
        },
        {
            "question": "Who is the CEO of Kala Pharmaceuticals?",
            "answer": "Mark Iwicki is the CEO of Kala Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Kala Pharmaceuticals headquartered?",
            "answer": "Kala Pharmaceuticals is headquartered in Watertown, Massachusetts, USA."
        },
        {
            "question": "What is INVELTYS?",
            "answer": "INVELTYS is a twice-daily eye drop formulation for the treatment of post-operative inflammation and pain following cataract surgery."
        },
        {
            "question": "When was Kala Pharmaceuticals founded?",
            "answer": "Kala Pharmaceuticals was founded in 2013."
        }
    ],
    "competitors": [
        "RGEN",
        "EYES",
        "OCUL"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}